CD8A and opsoclonus-myoclonus syndrome: We observed minimal CD8+ cells in several tumors with poor prognosis (0 to 1.3% of tumor lymphocytes) (n = 3), whereas in neuroblastoma tumors from patients with Opsoclonus Myoclonus Syndrome (OMS) (n = 2) a robust infiltration of CD8+ cells was noted (15.4 and 17.3% of tumor lymphocytes) (Fig 7A and 7B).